Brief: Innate's First NK Cell Engager Selected By Sanofi As Drug Candidate For Development

Innate Pharma SA

05/01/2021 06:03

Jan 5 (Reuters) - Innate Pharma Sa  IPH.PA :
    * REG-INNATE'S FIRST NK CELL ENGAGER SELECTED BY SANOFI  SASY.PA  AS DRUG
CANDIDATE FOR DEVELOPMENT
    * ANNOUNCED THAT SANOFI HAS MADE DECISION TO PROGRESS IPH6101/SAR443579 INTO
INVESTIGATIONAL NEW DRUG (IND)- ENABLING STUDIES
    * IN FIRST RESEARCH PROGRAM OF COLLABORATION, IPH6101/SAR443579 HAS SHOWN
ANTI-TUMOR ACTIVITY IN PRE-CLINICAL MODELS, INCLUDING ENCOURAGING
PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD) AND SAFETY DATA IN PRELIMINARY
NON-HUMAN PRIMATE STUDIES
    * AS WELL AS POSITIVE MANUFACTURABILITY PROPERTIES, LEADING TO ITS SELECTION
AS A
DRUG CANDIDATE FOR DEVELOPMENT
    * DECISION TRIGGERED A EUR 7M MILESTONE PAYMENT FROM SANOFI TO INNATE.
SANOFI WILL
BE RESPONSIBLE FOR ALL FUTURE DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION
OF IPH6101/SAR443579

Source text for Eikon:  ID:nGNE7K7htH 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))